Chemotherapy-induced anemia and oncologist perception on treatment: Results of a web-based survey

Tumori

Volumn 99, Issue 1, 2013, Pages 45-50

  Cortinovis, Diego ^a   Beretta, Giordano ^b   Piazza, Elena ^c   Luchena, Giovanna ^d   Aglione, Stefania ^e   Bertolini, Alessandro ^f   Buzzoni, Roberto ^g   Cabiddu, Mary ^h   Carnaghi, Carlo ⁱ   Danova, Marco ^j   Farina, Gabriella ^k   Ferrari, Vittorio ^l   Frascaroli, Mara ^m   Reni, Michele ⁿ   Tansini, Giuseppe ^o  

^a SAN GERARDO HOSPITAL   (Italy)

^b Humanitas Gavazzeni Hospital   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SANT ANNA HOSPITAL   (Italy)

^e DESIO HOSPITAL   (Italy)

^f Ospedale Civile   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h TREVIGLIO HOSPITAL   (Italy)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^j Ospedale Civile   (Italy)

^k FATEBENEFRATELLI HOSPITAL   (Italy)

^l SPEDALI CIVILI   (Italy)

^m IRCCS   (Italy)

ⁿ SAN RAFFAELE HOSPITAL   (Italy)

^o Lodi Hospital   (Italy)

more..

Author keywords

Blood transfusion; Chemotherapy induced anemia; Erythro Poietin; Survey

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; BIOSIMILAR AGENT; ERYTHROPOIETIN; IRON DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; CHEMICALLY INDUCED DISORDER; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; HEMATOLOGY; HUMAN; INTERNET; ITALY; MALE; MANPOWER; METHODOLOGY; MIDDLE AGED; ONCOLOGY; PHYSICIAN; PRESCRIPTION; QUESTIONNAIRE; SAMPLE SIZE; STATISTICS;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; BIOSIMILAR PHARMACEUTICALS; DRUG PRESCRIPTIONS; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FEMALE; HEALTH CARE SURVEYS; HEMATINICS; HEMATOLOGY; HUMANS; INTERNET; IRON COMPOUNDS; ITALY; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PHYSICIANS; QUESTIONNAIRES; RESEARCH DESIGN; SAMPLE SIZE;

MLCS; MLOWN;

EID: 84878139810     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161309900108     Document Type: Review

References (36)

1. Knight K, Wade S, Balducci L: Prevalence and outcomes of anaemia in cancer: a systematic review of the literature. Am J Med, 116 (Suppl 7A): 11S-26S, 2004.
2. Caro JJ, Salas M, Ward A, Goss G: Anaemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer, 91: 2214-2221, 2001.
3. Bohlius J, Tonia T, Schwarzer G: Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients. Acta Haematol, 125: 55-67, 2011.
4. FDA: An acceptable circular of information for the use of human blood and blood components. 2009. Available at http://www.fda.gov/downloads/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ UCM187348.pdf (accessed September 1, 2012).
5. Arcasoy MO: The non-haematopoietic biological effects of erythropoietin. Br J Haematol, 141: 14-31, 2008.
6. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancerassociated anemia. JAMA, 299: 914-924, 2008.
7. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet, 373: 1532-1542, 2009.
8. Bennett CL, McKoy JM, Henke M, Silver SM, MacDougall IC, Birgegård G, Luminari S, Casadevall N, Schellekens H, Sartor O, Lai SY, Armitage JO: Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park), 24: 260-268, 2010.
9. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer, 40: 2293-2306, 2004.
10. Hadlend BK, Longmore GD: Erythroid-stimulating agents in cancer therapy: potential danger and biological meachanisms. J Clin Oncol, 27: 4217-4226, 2009.
11. Luo W, Nordstrom BL, Fraeman K, Nordyke R, Ranganathan G, Linz HE, Winterkorn A, Stokes M, Ross SD, Knopf K: Adherence to guidelines for use of erythropoiesis stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006. J Clin Ther, 30: 2423-2435, 2008.
12. Henry DH, Langer CJ, McKenzie RS, Piech CT, Senbetta M, Schulman KL, Stepanski EJ: Hematologic outcomes and blood utilization in cancer patients with chemotherapyinduced anemia (CIA) pre-and post-national coverage determination (NCD): results from a multicenter chart review. Support Care Cancer, 20: 2089-2096, 2012.
13. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR; American Society of Clinical Oncology: American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol, 28: 4996-5010, 2010.
14. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst, 91: 1616-1634, 1999.
15. Balducci L: Anemia, fatigue and aging. Transf Clin Biol, 17: 375-381, 2010.
16. Kleinman L, Benjamin K, Viswanathan H, Mattera MS, Bosserman L, Blayney DW, Revicki DA: The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy. Qual Life Res, 21: 1255-1266, 2012.
17. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancerassociated anemia. JAMA, 299: 914-924, 2008.
18. Bohlius J, Schmidin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet, 373: 1532-1542, 2009.
19. Tonelli M, Hemmelgam B, Reiman T, Manns B, Reaume MN, Lloyd A, Wiebe N, Klarenbach S: Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ, 180: 62-71, 2009.
20. Ludwig H, Crawford J, Osteborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA: Pooled analysis of individual patient-level data from all randomized, doubleblind, placebo-controlled trials of darbepoietin alpha in the treatment of patients with chemotherapy-induced-anemia. J Clin Oncol, 27: 2838-2848, 2009.
21. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H: Erythropoiesisstimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer, 102: 301-315, 2010.
22. Hadland B, Longmore GD: Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J Clin Oncol, 25: 4217-4226, 2009.
23. Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B: Effects of erythropoietin receptors and erythropoiesisstimulating agents on disease progression in cancer. Br J Cancer, 106: 1249-1258, 2012.
24. Beguin Y: Erytropoietic agents and iron. In: Anaemia in Cancer, ESO Scientific updates, Bokemeyer C, Ludwig H (Eds), 2nd edition, Vol 6, p 199, Elsevier, 2005.
25. Hedenus M, Birgegard G: The role of iron supplementation during epoetin treatment for cancer-related anemia. Med Oncol, 26: 105-115, 2009.
26. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open label, randomized trial. J Clin Oncol, 22: 1301-1307, 2004.
27. Pedrazzoli P, Rosti G, Secondino S, Siena S: Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. Cancer, 115: 1169-1173, 2009.
28. Bastit L, Vanderbroek A, Altintas S, Gaede B, Pintér T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF: Randomized, multicenter controlled trial comparing the efficacy and safety of darbepoetin alpha administered every three weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol, 26: 1611-1618, 2008.
29. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, Lundin J, Lärfars G, Osterborg A: Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia, 21: 627-632, 2007.
30. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR: Intravenous ferric gluconate improves response to epoetin alpha versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist, 12: 231-242, 2007.
31. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J: Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant, 21: 378-382, 2007.
32. Auerbach M: Clinical update: intravenous iron for anaemia. Lancet 369: 1502-1504, 2007.
33. Szucs TD, Blank PR, Schwenkglenks M, Aapro M: Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer-or chemotherapyinduced anemia. Oncology, 81: 45-49, 2011.
34. Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K: Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alpha therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial. Med Oncol, 29: 2291-2299, 2012.
35. Jelkmann W: Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am J Hematol, 85: 771-780, 2010.
36. Schleyer TKL, Forrest JL: Methods for the design and administration of a web-based survey. Am Med Inform Assoc, 7: 416-425, 2000.